According to a recent analysis by market research firm Numerator, Ozempic users have slashed snack buying at supermarkets.
The food industry is still uneasy about the American anti-obesity craze, which is being fueled by GLP-1-based weight-loss medications like Wegovy and Mounjaro, which are manufactured by Novo Nordisk and Eli Lilly. This is because a recent study, which was cited by Morgan Stanley, indicates that households taking these medications are spending less money at the grocery store.
According to data provided by the recruiting website Glassdoor, the best places to work in America in 2024 are Bain & Company and Nvidia.
According to a recent analysis by market research firm Numerator, households taking GLP-1 medications spent 6% to 9% less each month on groceries than households not taking GLP-1 medications.
Sales of snacks, pastries, and ice cream decreased, but purchases of fish, veggies, and yogurt climbed in many GLP-1 homes.
According to MS, the January Numerator poll included information from almost 90,000 homes, and 12.3% of those households reported taking GLP-1 medications—a rise from 11.4% in October.
GLP-1 has primarily been used to address weight reduction, and MS noted that an increasing number of patients are paying for the medication out of pocket.
We questioned last year whether the GLP-1-induced anti-obesity mania in America would lead to a “food revolution.” Wall Street analysts swiftly noticed, downgrading several junk food firms, including Krispy Kreme, based on GLP-1 consequences.
Doug McMillon, the CEO of Walmart, stated in August of last year that customers who purchase drugs that suppress their appetite at in-store pharmacies are spending less on food:
“We still expect food, consumables, and health and wellness primarily due to the popularity of some GLP-1 drugs to grow as a percent of total in the back half.”
Additionally, Thanksgiving 2023 saw substantially smaller portion sizes for those who could afford to pay $1,000 a month for weight-loss medications.
Geoff Meacham, an analyst at Bank of America, recently stated in a different note that losing weight will start a “wardrobe replacement cycle.”
Even while mentioning GLP-1 on earnings calls has decreased…
According to the Goldman Sachs Global HLC GLP Risk Index, Wall Street is still loading up on Goldman’s GLP-1 Obesity Medicine basket in an attempt to profit from Americans losing weight while cutting firms that may have downstream risks associated with obesity drugs.
Make America Again Skinny.
